Home LiteratureArticle Details
PMID: 21710693 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.

The Journal of pathology ·Vol. 225 ·No. 2 ·2011-10-00 ·Pages 212-21

Grisanzio C, Seeley A, Chang M, Collins M, Di Napoli A, Cheng SC, Percy A, Beroukhim R, Signoretti S

Abstract

Renal cell carcinoma (RCC) is an aggressive malignancy with limited responsiveness to existing treatments. In vivo models of human cancer, including RCC, are critical for developing more effective therapies. Unfortunately, current RCC models do not accurately represent relevant properties of the human disease. The goal of this study was to develop clinically relevant animal models of RCC for preclinical investigations. We transplanted intact human tumour tissue fragments orthotopically in immunodeficient mice. The xenografts were validated by comparing the morphological, phenotypic and genetic characteristics of the kidney tumour tissues before and after implantation. Twenty kidney tumours were transplanted into mice. Successful tumour growth was detected in 19 cases (95%). The histopathological and immunophenotypic features of the xenografts and those of the original tumours largely overlapped in all cases. Evaluation of genetic alterations in a subset of 10 cases demonstrated that the grafts largely retained the genetic features of the pre-implantation RCC tissues. Indeed, primary tumours and corresponding grafts displayed identical VHL mutations. Moreover, an identical pattern of DNA copy amplification or loss was observed in 6/10 cases (60%). In summary, orthotopic engrafting of RCC tissue fragments can be successfully used to generate animal models that closely resemble RCC in patients. These models will be invaluable for in vivo preclinical drug testing and for deeper understanding of kidney carcinogenesis. The raw data of the SNP array analysis has been submitted to the GEO database (Accession No. GSE29062).

MeSH Terms
Adolescent Aged Aged, 80 and over Animals Carcinoma, Renal Cell/genetics,immunology,pathology Disease Models, Animal Female Humans Immunophenotyping Kidney Neoplasms/genetics,immunology,pathology Male Mice Mice, Inbred NOD Mice, SCID Middle Aged Transplantation, Heterologous
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Grisanzio Chiara
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Seeley Apryle
Chang Michelle
Collins Michael
Di Napoli Arianna
Cheng Su-Chun
Percy Andrew
Beroukhim Rameen
Signoretti Sabina
References (59)
59 references, click to expand
  1. Orthotopic models are necessary to predict therapy of transplantable tumors in mice.
    Cancer Metastasis Rev. 1998-1999;17(3):279-84 PMID: 10352881
  2. Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis.
    Cancer Res. 2004 Mar 1;64(5):1712-21 PMID: 14996731
  3. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis.
    Cancer. 2007 May 1;109(9):1763-8 PMID: 17351954
  4. A clinically relevant orthotopic implantation nude mouse model of human epithelial ovarian cancer--based on consecutive observation.
    Int J Gynecol Cancer. 2005 Sep-Oct;15(5):850-5 PMID: 16174235
  5. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
    Br J Cancer. 2001 May 18;84(10):1424-31 PMID: 11355958
  6. Familial renal adenomas in Wistar rats; a preliminary report.
    Acta Pathol Microbiol Scand. 1954;34(6):554-62 PMID: 13206757
  7. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology.
    Cancer Res. 1995 Dec 15;55(24):6189-95 PMID: 8521412
  8. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models.
    Gynecol Oncol. 2005 Jan;96(1):48-55 PMID: 15589579
  9. Profiling and classification tree applied to renal epithelial tumours.
    Histopathology. 2008 Jan;52(2):158-66 PMID: 18036175
  10. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
    Clin Cancer Res. 2005 May 15;11(10):3714-21 PMID: 15897568
  11. Renal-cell carcinoma.
    N Engl J Med. 2005 Dec 8;353(23):2477-90 PMID: 16339096
  12. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
    Cancer. 2009 May 15;115(10 Suppl):2306-12 PMID: 19402073
  13. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms.
    Clin Lab Med. 2005 Jun;25(2):247-57 PMID: 15848735
  14. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
    Cancer. 2009 Aug 15;115(16):3618-30 PMID: 19479976
  15. CD34- blood-derived human endothelial cell progenitors.
    Stem Cells. 2001;19(4):304-12 PMID: 11463950
  16. Epidemiologic aspects of renal cell carcinoma.
    Semin Oncol. 2006 Oct;33(5):527-33 PMID: 17045081
  17. Renal cell carcinoma.
    Lancet. 2009 Mar 28;373(9669):1119-32 PMID: 19269025
  18. Prognostic factors for survival in metastatic renal cell carcinoma: update 2008.
    Cancer. 2009 May 15;115(10 Suppl):2273-81 PMID: 19402065
  19. Orthotopic implantation of colon carcinoma cells provides an experimental model in the rat that replicates the regional spreading pattern of human colorectal cancer.
    Cancer Lett. 1998 Oct 23;132(1-2):127-33 PMID: 10397463
  20. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
    Clin Cancer Res. 2003 Feb;9(2):802-11 PMID: 12576453
  21. Cancer statistics, 2009.
    CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 PMID: 19474385
  22. Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis.
    Arch Pathol Lab Med. 2007 Aug;131(8):1290-7 PMID: 17683191
  23. Genetic basis of cancer of the kidney.
    Semin Oncol. 2006 Oct;33(5):544-51 PMID: 17045083
  24. Immunotherapy of metastatic renal cell carcinoma.
    Cancer J. 2008 Sep-Oct;14(5):320-4 PMID: 18836337
  25. Cancer seed and soil can be highly selective: human-patient colon tumor lung metastasis grows in nude mouse lung but not colon or subcutis.
    Anticancer Res. 1995 May-Jun;15(3):795-8 PMID: 7645960
  26. Renal-cell carcinoma.
    N Engl J Med. 1996 Sep 19;335(12):865-75 PMID: 8778606
  27. Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model.
    BMC Cancer. 2007 Jan 09;7:4 PMID: 17212824
  28. Chemotherapy for advanced renal-cell carcinoma: 1983-1993.
    Semin Oncol. 1995 Feb;22(1):42-60 PMID: 7855619
  29. Immunotherapy of metastatic renal cell carcinoma.
    Cancer. 2009 May 15;115(10 Suppl):2298-305 PMID: 19402060
  30. Hereditary renal cell carcinoma in the Eker rat: a unique animal model for the study of cancer susceptibility.
    Toxicol Lett. 1995 Dec;82-83:621-5 PMID: 8597118
  31. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue.
    Prostate. 2005 Jul 1;64(2):149-59 PMID: 15678503
  32. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization.
    Am J Pathol. 1999 Jul;155(1):267-74 PMID: 10393858
  33. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):758s-763s PMID: 17255306
  34. Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes.
    Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2854-8 PMID: 7708737
  35. Immunotherapy for metastatic renal cell carcinoma.
    BJU Int. 2007 May;99(5 Pt B):1282-8 PMID: 17441925
  36. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture.
    Cancer Res. 1990 Oct 1;50(19):6130-8 PMID: 1698118
  37. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.
    Eur Urol. 2011 Apr;59(4):619-28 PMID: 21167632
  38. Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation.
    J Pathol. 1998 Aug;185(4):382-8 PMID: 9828836
  39. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74 PMID: 17160391
  40. Prognostic value of Ki-67 expression in renal cell carcinomas.
    Eur Urol. 1997;31(3):350-5 PMID: 9129930
  41. Hereditary renal adenomas and adenocarcinomas in rats.
    Diagn Histopathol. 1981 Jan-Mar;4(1):99-110 PMID: 7249912
  42. Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts.
    Eur J Cancer. 1990;26(8):901-5 PMID: 2145936
  43. Rising incidence of small renal masses: a need to reassess treatment effect.
    J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4 PMID: 16985252
  44. Systemic therapy for renal cell carcinoma.
    J Urol. 2000 Feb;163(2):408-17 PMID: 10647643
  45. Molecular cytogenetics of renal cell tumors.
    Adv Cancer Res. 1993;62:89-124 PMID: 8109322
  46. CD10 is a diagnostic and prognostic marker in renal malignancies.
    Histopathology. 2004 Nov;45(5):460-7 PMID: 15500649
  47. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.
    Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S134-9 PMID: 14508091
  48. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors.
    Am J Pathol. 2010 Apr;176(4):1901-13 PMID: 20167861
  49. Incidence and long-term prognosis of papillary renal cell carcinoma.
    J Cancer Res Clin Oncol. 2009 Jun;135(6):799-805 PMID: 19023595
  50. Orthotopic transplantation model of human gastrointestinal cancer and detection of micrometastases.
    World J Gastroenterol. 2001 Jun;7(3):381-6 PMID: 11819794
  51. Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection.
    Clin Exp Metastasis. 1999 May;17(3):265-70 PMID: 10432012
  52. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
    Clin Cancer Res. 2010 Jul 15;16(14):3628-38 PMID: 20606035
  53. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.
    Cancer Res. 2009 Jun 1;69(11):4674-81 PMID: 19470766
  54. A novel "Nihon" rat model of a Mendelian dominantly inherited renal cell carcinoma.
    Jpn J Cancer Res. 2000 Nov;91(11):1096-9 PMID: 11092972
  55. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Cancer Res. 2004 Oct 1;64(19):7099-109 PMID: 15466206
  56. Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization.
    Cancer Res. 1998 Jun 1;58(11):2304-9 PMID: 9622063
  57. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.
    Curr Oncol Rep. 2009 Mar;11(2):94-101 PMID: 19216840
  58. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF.
    Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4299-304 PMID: 20154271
  59. Mouse xenograft models vs GEM models for human cancer therapeutics.
    Dis Model Mech. 2008 Sep-Oct;1(2-3):78-82 PMID: 19048064
Article Info
Journal
The Journal of pathology
Abbr.
J Pathol
ISSN
1096-9896
Published
2011-10-00
Epub
2011-00-27
Pages
212-21
Language
English
Region
England
NLM ID
0204634
PMCID
PMC3793840
Subset
IM
Grants
NCI NIH HHS · K08CA122833 · United States
NCI NIH HHS · K08 CA122833-05 · United States
NCI NIH HHS · P50 CA101942-09 · United States
NCI NIH HHS · K08 CA122833 · United States
NCI NIH HHS · P50 CA101942-07 · United States
Databases
GEO
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com